RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
← Back to Research Library
Mechanism of Action
Retatrutide (LY3437943) is a first-in-class triple GIP/GLP-1/glucagon receptor agonist. The glucagon component activates hepatic lipid oxidation, increases energy expenditure through thermogenesis, and promotes ketogenesis. Triple receptor engagement produces synergistic effects exceeding dual agonists.
Key Research Findings
- Phase 2: 24.2% mean weight loss at 12mg over 48 weeks — largest pharmacological weight loss reported
- Nearly 100% of participants at highest dose achieved >=5% weight loss
- Hepatic fat reduction of ~82% from baseline in liver fat sub-study
Peer-Reviewed Studies (2)
Jastreboff AM, Kaplan LM, et al.
New England Journal of Medicine (2023)
Retatrutide produced up to 24.2% weight loss at 48 weeks in 338 participants
Rosenstock J, Frias JP, et al.
Lancet (2023)
Superior glycemic control with up to 2.02% HbA1c reduction plus 16.9% weight loss in T2DM
Research Disclaimer: The studies referenced above are from publicly available peer-reviewed literature. Pepta Labs products are sold strictly for research purposes. They are not intended for human consumption, therapeutic use, or as dietary supplements. All information is provided for educational and research reference only.